135 related articles for article (PubMed ID: 9416790)
1. Oral platinum analogue JM216, a radiosensitizer in oxic murine cells.
van de Vaart PJ; Klaren HM; Hofland I; Begg AC
Int J Radiat Biol; 1997 Dec; 72(6):675-83. PubMed ID: 9416790
[TBL] [Abstract][Full Text] [Related]
2. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
3. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Mellish KJ; Kelland LR
Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
[TBL] [Abstract][Full Text] [Related]
5. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
6. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
Amorino GP; Freeman ML; Carbone DP; Lebwohl DE; Choy H
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):399-405. PubMed ID: 10760436
[TBL] [Abstract][Full Text] [Related]
7. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
Raynaud FI; Odell DE; Kelland LR
Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
[TBL] [Abstract][Full Text] [Related]
8. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
9. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
11. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of low-energy electrons.
Rezaee M; Hunting DJ; Sanche L
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):847-53. PubMed ID: 23910707
[TBL] [Abstract][Full Text] [Related]
12. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
[TBL] [Abstract][Full Text] [Related]
13. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
van de Vaart PJ; van der Vange N; Zoetmulder FA; van Goethem AR; van Tellingen O; ten Bokkel Huinink WW; Beijnen JH; Bartelink H; Begg AC
Eur J Cancer; 1998 Jan; 34(1):148-54. PubMed ID: 9624250
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40).
Begg AC; van der Kolk PJ; Emondt J; Bartelink H
Radiother Oncol; 1987 Jun; 9(2):157-65. PubMed ID: 3303163
[TBL] [Abstract][Full Text] [Related]
16. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
Reardon JT; Vaisman A; Chaney SG; Sancar A
Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
[TBL] [Abstract][Full Text] [Related]
17. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
18. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]